Merck & Co Inc (LSE:0QAH)
$ 100 0 (0%) Market Cap: 252.20 Bil Enterprise Value: 275.80 Bil PE Ratio: 20.90 PB Ratio: 5.67 GF Score: 87/100

Merck & Co Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 10, 2020 / 12:00PM GMT
Release Date Price: $82.48
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

Good morning, or good afternoon to those of you in Europe.

This is Andrew Baum from Citi's global health care team, delighted to introduce our next session.

As you'll see from the roster of familiar faces above me, we have the management from Merck, namely Roy Baynes, the Chief Development Officer and Chief Medical Officer; and Peter Dannenbaum, the Head of Investor Relations. Many thanks, both of you, for joining us.

We've got about 45 minutes. I want to keep it a free-flowing discussion. (Operator Instructions)

Questions & Answers

Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So maybe a leading question, to start. A criticism that we get from investors, and obviously we've been a very long-term bull of immuno-oncology and Merck in particular, is that there is too much dependency on KEYTRUDA. The durability of KEYTRUDA is questioned in terms of biosimilar entrants. And more

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot